RXST - NASDAQ

RxSight, Inc.

RXST·NASDAQ

$4.79

-2.3%

HealthcareMedical - Devices

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$198.29M

EPS-0.9500

P/E Ratio-5.04

Earnings Date08/06/2026

311.81M

Assets

-2%

3Y+108.0%

5Y+210.0%

10Y+182.0%

36.13M

Total Liabilities

-3%

3Y-40.0%

5Y-91.0%

10Y-91.0%

275.68M

Total Equity

-2%

3Y+207.0%

5Y-193.0%

10Y-191.0%

RxSight, Inc. Funding & Solvency Profile

RXST · NASDAQ

Current Assets

Cash & Cash Equivalents19.95M

Net Receivables23.38M

Inventory31.56M

Other Current Assets4.39M

Total Current Assets287 M

Non-Current Assets

Property, Plant & Equipment23.02M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets1.34M

Total Non-Current Assets24 M

Total Assets

311.81M

Financial Health Analysis

Current Ratio

10.95x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.13x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

261 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

92% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

RxSight, Inc. Balance Sheet

RXST • NASDAQ

RxSight, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	19.9M	16.7M	9.7M	11.8M	24.4M	14M	8M
Short-Term Investments	208.2M	220.5M	117.5M	94M	135M	55M	72.7M
Cash & Short-Term Investments	228.1M	237.2M	127.2M	105.8M	159.3M	69M	80.7M
Net Receivables	23.4M	30.1M	20.3M	11M	4.9M	2.9M	789K
Accounts Receivables	23.4M	30.1M	20.3M	11M	4.9M	2.9M	789K
Inventory	31.6M	22M	17.4M	14.8M	8M	8.3M	7.2M
Prepaids	0.0	0.0	0.0	0.0	4.1M	1.4M	1.5M
Other Current Assets	4.4M	4.5M	3.5M	3M	0.0	0.0	0.0
Total Current Assets	287.5M	293.8M	168.4M	134.6M	176.3M	81.5M	90.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	23M	23.6M	13.3M	14.1M	15.5M	18.6M	19.3M
Long-Term Investments	0.0	750K	711K	0.0	0.0	0.0	0.0
Other Non-Current Assets	1.3M	360K	147K	1.5M	925K	571K	983K
Total Non-Current Assets	24.4M	24.7M	14.1M	15.6M	16.4M	19.2M	20.2M
Total Assets	311.8M	318.6M	182.6M	150.2M	192.7M	100.7M	110.4M
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.3M	4.5M	3.9M	2.6M	1.7M	1.1M	2.2M
Accounts Payable	5.3M	4.5M	3.9M	2.6M	1.7M	1.1M	2.2M
Accrued Expenses	0.0	0.0	10.6M	455K	319K	0.0	0.0
Short Term Debt	1.2M	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	974K	1.8M	2M	1.5M	1.3M	990K
Deferred Revenue	0.0	3.1M	2M	1.3M	618K	417K	378K
Other Current Liabilities	19.8M	17.2M	2.6M	10.9M	6.9M	8.8M	4.9M
Total Current Liabilities	26.3M	25.9M	20.9M	17.2M	11.1M	11.6M	8.5M
NON-CURRENT LIABILITIES
Long Term Debt	9.9M	0.0	0.0	40.2M	39.8M	24.4M	0.0
Other Non-Current Liabilities	0.0	127K	74K	0.0	0.0	357.1M	402.1M
Total Non-Current Liabilities	9.9M	11.4M	1.3M	43M	43.4M	386.6M	406.6M
Capital Lease Obligations	0.0	12.3M	3M	4.8M	5.2M	6.4M	5.5M
Total Liabilities	36.1M	37.3M	22.2M	60.3M	54.5M	398.2M	415M
SHAREHOLDERS' EQUITY
Common Stock	41K	40K	36K	28K	27K	80.8M	56.4M
Additional Paid-In Capital	0.0	903.1M	755M	636M	617.5M	0.0	0.0
Retained Earnings	-661M	-622.1M	-594.6M	-546M	-479.3M	-430.6M	-419.9M
Accumulated Other Comprehensive Income/Loss	53K	166K	-5K	-95K	-20K	-3K	46K
Other Total Stockholders' Equity	936.6M	0.0	0.0	0.0	0.0	52.3M	58.8M
Total Stockholders' Equity	275.7M	281.2M	160.4M	89.9M	138.2M	-297.5M	-304.6M
Total Equity	275.7M	281.2M	160.4M	89.9M	138.2M	-297.5M	-304.6M
SUMMARY
Total Liabilities & Equity	311.8M	318.6M	182.6M	150.2M	192.7M	100.7M	110.4M
Total Investments	208.2M	220.5M	118.2M	94M	135M	55M	72.7M
Total Debt	11M	12.3M	3M	45M	44.9M	30.8M	5.5M
Net Debt	-8.9M	-4.4M	-6.7M	33.2M	20.6M	16.8M	-2.4M
Shares Outstanding	41,116,600	41,116,600	41,116,600	41,116,600	41,116,600	41,116,600	41,116,600

SEC Filings

RXST - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	April 27, 2026	2026	View Filing
8-K/A 8-K/A 2026 (Amended) N/A	March 19, 2026	January 11, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 11, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 23, 2025	December 23, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 22, 2025	December 16, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 19, 2025	December 18, 2025	2025	View Filing

Showing 1 to 10 of 75 filings

Related Guides

Blog Categories

Continue your RXST research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.